GlassScriptPhysician profile
Yaser Alobeid
NPI 1396792461
$7,915.12
in general payments reported to CMS, 2019-2025
36 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,597 · 2020: $823 · 2021: $1,157 · 2022: $1,936 · 2023: $767 · 2024: $536 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,401.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,089.58 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,053.55 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $767.04 | 2019-2024 | Otezla, Repatha |
| Merz North America, INC. | $764.18 | 2021-2022 | |
| Abbvie INC. | $722.08 | 2021-2025 | Ubrelvy, Vraylar |
| Lilly USA, LLC | $631.03 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $569.26 | 2019-2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $305.60 | 2019-2022 | |
| Vivus LLC | $222.77 | 2021-2023 | Qsymia |
| Pfizer INC. | $217.94 | 2021-2025 | |
| Glaxosmithkline, LLC. | $191.19 | 2019-2025 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $175.38 | 2022-2024 | Quviviq |
| Madrigal Pharmaceuticals | $171.99 | 2025 | Rezdiffra |
| Almatica Pharma LLC | $113.90 | 2024-2025 | Loreev Xr |
| Merck Sharp & Dohme LLC | $113.37 | 2021-2023 | Verquvo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $98.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $94.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.83 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $67.26 | 2020-2021 | |
| Abbott Laboratories | $55.16 | 2022-2025 | Freestyle Libre 3 |
| Bausch Health US, LLC | $47.41 | 2022-2023 | Aplenzin, Wellbutrin |
| Aimmune Therapeutics, INC. | $46.87 | 2025 | Zenpep |
| Astellas Pharma US INC | $46.14 | 2024-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $45.42 | 2021 | |
| Lundbeck LLC | $28.18 | 2024 | Vyepti |
| Corcept Therapeutics | $26.14 | 2023 | Korlym |
| Axsome Therapeutics, INC. | $26.13 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $21.84 | 2021 | |
| Indivior INC. | $18.66 | 2019 | |
| Dexcom, INC. | $16.85 | 2022 | |
| Endo Pharmaceuticals INC. | $15.68 | 2021 | |
| Exact Sciences Corporation | $15.67 | 2023 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $14.53 | 2023 | Edarbi |
| Jazz Pharmaceuticals INC. | $13.57 | 2021 | |
| Allergan, INC. | $13.43 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaser Alobeid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.